Skip to main content
Top
Literature
1.
go back to reference Montenegro-Garreaud X, Miranda RN, Reynolds A, Tang G, Wang SA, Yabe M et al (2017) Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase. Hum Pathol 65:147–156CrossRef Montenegro-Garreaud X, Miranda RN, Reynolds A, Tang G, Wang SA, Yabe M et al (2017) Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase. Hum Pathol 65:147–156CrossRef
2.
go back to reference Fioretos T, Panagopoulos I, Lassen C, Swedin A, Billström R, Isaksson M et al (2001) Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chromosom Cancer 32:302–310CrossRef Fioretos T, Panagopoulos I, Lassen C, Swedin A, Billström R, Isaksson M et al (2001) Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chromosom Cancer 32:302–310CrossRef
3.
go back to reference Barnes EJ, Leonard J, Medeiros BC, Druker BJ, Tognon CE (2020) Functional characterization of two rare BCR-FGFR1+ leukemias. Cold Spring Harb Mol Case Stud 6:a004838CrossRef Barnes EJ, Leonard J, Medeiros BC, Druker BJ, Tognon CE (2020) Functional characterization of two rare BCR-FGFR1+ leukemias. Cold Spring Harb Mol Case Stud 6:a004838CrossRef
4.
go back to reference Patkar N, Bhanshe P, Rajpal S, Joshi S, Chaudhary S, Chatterjee G et al (2020) NARASIMHA: novel assay based on targeted RNA sequencing to identify chimeric gene fusions in hematological malignancies. Blood Cancer J 10:50CrossRef Patkar N, Bhanshe P, Rajpal S, Joshi S, Chaudhary S, Chatterjee G et al (2020) NARASIMHA: novel assay based on targeted RNA sequencing to identify chimeric gene fusions in hematological malignancies. Blood Cancer J 10:50CrossRef
5.
go back to reference Peiris MN, Meyer AN, Nelson KN, Bisom-Rapp EW, Donoghue DJ (2020) Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation. Haematologica 105(5):1262–1273CrossRef Peiris MN, Meyer AN, Nelson KN, Bisom-Rapp EW, Donoghue DJ (2020) Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation. Haematologica 105(5):1262–1273CrossRef
Metadata
Title
Myeloid Neoplasm with t(8;22)(p11;q11): A Mimicker of Chronic Myeloid Leukaemia in Blast Crisis
Authors
Gargi Kapatia
Arun Sasikumar Nair Remani
Shano Naseem
Mayur Parihar
Sreejesh Sreedharanunni
Publication date
01-04-2021
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2021
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01343-3

Other articles of this Issue 2/2021

Indian Journal of Hematology and Blood Transfusion 2/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine